- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
Metastasis Directed- and Hormone Therapy Extends PFS in Oligometastatic Prostate Cancer
December 06, 2022
In an interview with Targeted Oncology, Chad Tang, MD, The University of Texas MD Anderson Cancer Center, discussed background and implication of findings from the EXTEND trial.
Tucatinib, Trastuzumab, and Capecitabine for Leptomeningeal Metastases in Breast Tumors
December 05, 2022
Erica Stringer-Reasor, MD, discusses the leptomeningeal metastases in patients with breast cancer and an FDA-approved targeted therapy/chemotherapy combination that is being studied as a treatment.
Discussing Data on Efficacy and Adverse Events of Mobocertinib for NSCLC
December 05, 2022
During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, PhD, discussed with participants the adverse event management and expected efficacy of mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion. This is the second of 2 articles based on this event.
ClonoSeq ctDNA-based MRD Assay Launched for Patients With DLBCL
December 05, 2022
Adaptive Biotechnologies announced the launch of its clonoSEQ ctDNA-based MRD assay for patients with diffuse large B-cell lymphoma.
Emerging Research in the Chronic Lymphocytic Leukemia Space
December 05, 2022
Alexey Danilov, MD, PhD, provides an overview on the recent updates and research in the chronic lymphocytic leukemia space.
177Lu-PSMA-617 Demonstrates Significant rPFS Benefit in PSMA-Positive mCRPC
December 05, 2022
In patients with PSMA-positive metastatic castration-resistant prostate cancer, the PSMA-directed therapy with 177Lu-PSMA-617, led to significant improvement in radiographic progression-free survival.
FDA Clears IND for BEAM-201 in Relapsed/Refractory T-ALL/T-LL
December 05, 2022
The clinical hold for the development of BEAM-201 has been lifted, allowing investigators to assess the agent in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/ T-cell lymphoblastic lymphoma.
FDA Considers BLA for I/ONTAK for the Treatment of Persistent or Recurrent CTCL
December 05, 2022
The FDA will conduct a regular review of the application submitted for approval of I/ONTAK in patients with persistent or recurrent cutaneous T-cell lymphoma.
Biomarkers in Renal Cell Carcinoma: Present Utility and Future Possibility
December 05, 2022
Wenxin (Vincent) Xu, MD, provides insight on biomarkers in renal cell carcinoma.
Remaining Checkpoint Inhibitor Combinations Remains Key at Melanoma Conference
December 04, 2022
Refining current regimens and other emerging approaches will be delineated in melanoma, according to Omid Hamid, MD.
BI 1810631 Shows Early Antitumor Activity in NSCLC
December 04, 2022
Although HER2 mutations present in many solid tumors, lung cancer is of particular interest because a significant number of mutations are found in the tyrosine kinase domain of the gene. Of those, about 90% take the form of insertions or deletions, according study findings.
Novel MPS1 Inhibitor Shows Early Signs of Activity in Third-line HCC
December 03, 2022
In data from a first-in-human study of a novel MPS1 inhibitor in patients with advanced solid tumors, clinical activity was observed.